Compare NTRA & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTRA | KVUE |
|---|---|---|
| Founded | 2003 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Specialty Chemicals |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.9B | 33.1B |
| IPO Year | 2015 | 2023 |
| Metric | NTRA | KVUE |
|---|---|---|
| Price | $208.72 | $18.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 12 |
| Target Price | ★ $253.79 | $19.58 |
| AVG Volume (30 Days) | 1.1M | ★ 62.1M |
| Earning Date | 02-27-2026 | 02-17-2026 |
| Dividend Yield | N/A | ★ 4.47% |
| EPS Growth | N/A | ★ 35.31 |
| EPS | N/A | ★ 0.75 |
| Revenue | $2,116,676,000.00 | ★ $15,006,000,000.00 |
| Revenue This Year | $33.95 | N/A |
| Revenue Next Year | $16.72 | $2.72 |
| P/E Ratio | ★ N/A | $24.81 |
| Revenue Growth | ★ 38.17 | N/A |
| 52 Week Low | $125.38 | $14.02 |
| 52 Week High | $256.36 | $25.17 |
| Indicator | NTRA | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 35.85 | 74.70 |
| Support Level | $203.86 | $17.96 |
| Resistance Level | $213.96 | $18.97 |
| Average True Range (ATR) | 8.54 | 0.37 |
| MACD | -2.07 | 0.10 |
| Stochastic Oscillator | 23.88 | 84.96 |
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced November 2025 that it signed a deal to be fully acquired by Kimberly-Clark with the deal expected to close during the second half of 2026.